Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity

June 8, 2017 | Press Releases

PCCTC study serves as the foundation for a therapeutically relevant classification of prostate cancer.

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.